



Stifel 2020 Virtual Healthcare Conference

*Anthony Fernando, President & CEO
Shameze Rampertab, CFO*

November 17, 2020

FORWARD LOOKING STATEMENTS



This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the market development activities related to the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, the impact on the ongoing pandemic on our business and our customers, our current cash reach, the effect on our business on existing and new regulatory requirements and other economic and competitive factors and whether we will be able to execute upon our corporate objectives. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OUR STRATEGIC INTENT

At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today's value-based healthcare environment.

TRANSENERIX (NYSE American:TRXC)

EARLY-COMMERCIAL STAGE COMPANY USHERING IN A NEW ERA OF
MINIMALLY INVASIVE SURGERY



- **Senhance Surgical Robotic System** – the first and only **Digital Laparoscopy** platform
- Significant and differentiated addressable market opportunity
- FDA Cleared, CE Marked and Japan PMDA approved
- Building awareness and ramping up clinical adoption
- Well positioned to bring Augmented Intelligence (AI) and Machine Vision to surgery

COMPANY SNAPSHOT

FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL
ROBOTICS IN NEARLY 20 YEARS




Active sites in the
U.S., E.U. and Asia

3,700+ Surgeries
Performed, to date



140 global employees

100+
Surgeon Users



GLOBAL TRENDS IN ROBOTIC SURGERY

SURGICAL ROBOTICS IS A LARGE AND FAST GROWING MARKET
AND LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY



VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION

THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER
THE CONSTRAINTS OF VALUE-BASED HEALTHCARE



OR
Inefficiencies



Surgical
Variability



Workforce
Challenges



**Laparoscopy is the most
widely performed surgical
technique and carries
limitations that compound
these factors and can
impact clinical outcomes**

Digital laparoscopy seeks to address these limitations

WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY



AN OPPORTUNITY AND NEED TO ADD TO THE WAYS SURGICAL
ROBOTICS CREATES VALUE



Senhance



Da Vinci

	Digital Laparoscopy		Robotic Assisted Surgery	
	Feature	Implication	Feature	Implication
Motion	▪ Lap	▪ Familiarity for laparoscopic surgeons	▪ Open	▪ More enabling for non-laparoscopists
Instruments	▪ Fully reusable	▪ Low cost per procedure	▪ Limited Use (10x max)	▪ High cost per procedure
	▪ 5mm and 3mm	▪ Advances MIS benefit	▪ 8mm	▪ Not improving invasiveness over laparoscopy
Additional Features	▪ Haptic feedback	▪ Restores significant sensory input	▪ Wristed instruments	▪ Enabling but higher cost per procedure
	▪ Eye tracking camera control	▪ Novel surgical vision control		
	▪ Open vision system	▪ Leverage best in class visualization technologies		
	▪ Individual boom arms	▪ Full patient access		
	▪ Articulating instruments	▪ Enabling where needed		

Standard Laparoscopic tools, digital information and decision support tools will be the primary driver of the added value through computer assistance

Competitors are following the Da Vinci model

SENHANCE SYSTEM ADDRESSES KEY CHALLENGES FACING HOSPITALS AND LAPAROSCOPIC SURGEONS

BUILDING THE BRIDGE FROM LAPAROSCOPY TO ROBOTICS



First robotic system with
*Augmented Intelligence (AI)
and Machine Vision
Capabilities*


First robotic system to
*offer the security of haptic
feedback*

First robotic system to
*offer simultaneous surgeon-
controlled visualization*

86 different types of
*procedure/technique
surgeries performed*

*New standard in minimally
invasive surgery with **3mm**
instruments*

*Developed broad instrument
portfolio with **70**
instruments in the catalog*




STRONG, BROAD-BASED CLINICAL PERFORMANCE




SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE
ACROSS THE THREE MAJOR GEOGRAPHIES

GLOBAL CLINICAL CASE VOLUME TREND



Strong clinical case performance in 2019
Strong momentum in Q1 2020 dampened by COVID

2019/2020 CASE MIX




Adoption across multiple specialty areas,
demonstrating broader applicability and adoption


* TransEnterix Estimates and YTD Actual

DIGITAL LAPAROSCOPY PLATFORM – MORE THAN THE ROBOT

OUR VISION FOR DIGITAL LAPAROSCOPY GOES BEYOND THE ROBOT




**ROBOTIC
MANIPULATION**




**OPEN PLATFORM
ARCHITECTURE**




**INTELLIGENT
SCENE COGNITION**



**AUGMENTED
INTELLIGENCE**



CONNECTIVITY



**OPERATING ROOM
WORKFLOW**

THE FIRST MACHINE VISION SYSTEM IN ROBOTIC SURGERY

LEADING THE WAY IN AUGMENTED INTELLIGENCE AND MACHINE VISION IN SURGERY


SENHANCE INTELLIGENT SURGICAL UNIT (ISU)




FDA 510(k) Approved
in March 2020




In Clinical use in
the US



DEFECT IDENTIFICATION AND SIZING



3D POINT TO POINT MEASUREMENT



CRITICAL STRUCTURE IDENTIFICATION



FUTURE FEATURE
ADDITIONS

Our Plan for 2020

2020 – SENHANCE AND DIGITAL LAPAROSCOPY RECOGNIZED AS KEY COMPONENTS FOR ROBOTIC GROWTH



WE ARE FOCUSED ON:

MARKET DEVELOPMENT

- Expand the number of sites using the Senhance System in key geographies
- Double the number of clinical cases
- Increase the number of speakers & advocates cascading our key messages

CLINICAL EVIDENCE

- Publication of evidence supporting Senhance value propositions
 - Cost Effectiveness
 - Clinical Outcomes
 - O.R. Efficiency
 - Ergonomics

PORTFOLIO EXPANSION

- Scene cognition and Augmented Intelligence technology launched in the US
- Full EU launch of 5mm Articulating instruments
- Indication expansion
 - Pediatrics in EU
 - General Surgery in US
 - Bariatric in US

**By End 2020 – Critical mass of advocacy, awareness, and credibility
developed as a foundation to drive future growth**

Key Operational Accomplishments

2020 OPERATIONAL HIGHLIGHTS

SIGNIFICANT OPERATIONAL PROGRESS YEAR TO DATE


- Nine Senhance lease agreements signed, 8 clinical programs initiated and completed ~1,200+ cases YTD
- Received FDA clearance and completed first surgical procedures using Augmented Intelligence(AI) and machine vision system, Intelligent Surgical Unit (ISU)
- Received CE Mark and completed first surgical procedures for pediatric use of Senhance with 3 mm instruments in Europe
- Made FDA 510(k) submission for General Surgery indication expansion
- Established Asia Pacific Training Center at Saitama Medical University International Medical Center in Japan



MILESTONES SUPPORT OPERATIONAL GROWTH



REGULATORY SUCCESS AND PEER REVIEWED PUBLICATIONS

- 
- A vertical timeline graphic consisting of a central vertical line with five circular nodes. Each node is connected to a text block describing a milestone.
- Receive CE Mark for ISU in Europe, Q4 2020
 - Receive FDA 510(K) for General Surgery indication expansion, Q1 2021
 - File FDA 510(K) for next generation ISU, Q1 2021
 - File FDA 510(k) for articulating instruments, Q1 2021
 - Publish papers in peer reviewed journals, Q1/Q2 2021
 - Health-economic studies of Senhance, laparoscopy and robotics
 - Clinical performance
 - Operating room efficiency and surgeon ergonomics



